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Background
Based on the current knowledge of the Systemic onset
Juvenile Idiopathic Arthritis (SoJIA) physiopathology,
Anakinra is an emergent drug in its treatment. Initially
we used it as a second-line treatment, however accord-
ing with some reports of its efficacy in the induction of
remission with an earlier use, we have started to use as
a first-line therapy.
Aim
To describe the response to anakinra in our patients
with SoJIA, and to compare the differences in the treat-
ment with anakinra as a first or second-line drug.
Methods
Retrospective review of the patients treated with Ana-
kinra in our pediatric rheumatology service since 2005.
Clinical and analytical data were registered at the begin-
ning of the symptoms, at diagnose and at follow-up (on
days 1-3, 7-14, 30 and 3-6 months after starting on Ana-
kinra). SPSS Statistics 19.0 software was used for statisti-
cal analysis.
Results
Among 23 patients treated with Anakinra, in 3 (13%)
patients it has been used as a first-line drug without
corticosteroids (group A), in 5 (22%) as a first-line with
corticosteroids (group B) and in 15 (65%) patients Ana-
kinra was used as a second-line treatment when others
DMARDs failed to control the disease (group C). There
were no statistical differences in sex, age of diagnose
of SoJIA and in the initial dose of Anakinra (median of
2.5 mg/kg/day) between groups. The median time
between the initial symptoms of SoJIA and the start of
Anakinra was 21 days (A), 43 days (B) and 175 days (C)
(p 0.025). At 1-3 days, 7-14 days, 30 days and 3-6
months after starting Anakinra a statistical significant
reduction of the values of CRP, ESR, ferritin and white
blood cells was observed in all the patients, without sta-
tistical differences between groups. The analytical para-
meter which experienced a faster reduction was CRP
with a median of reduction at 1-3 days of 78.92% (A),
75.95% (B) and 83.93% (C). Adverse effects were regis-
tered in 5 of 23 patients (21.7%): 2 in group A, 1 in
group B and 2 in C. They consist in 3 hypersensitivity
reactions (2 in group A, and 1 in group C), elevation of
transaminases not explained by other cause in one
patient of group B (with normalization after stopping
Anakinra), and death due to sepsis in a patient of group
C (patient with a Kabuki syndrome and a severe pul-
monary affection, alveolar proteinosis). In the group
treated exclusively with Anakinra, the treatment was
stopped after 110 days in one patient for clinical and
analytical remission; in the other two, the initial
response was clinically and analytically satisfactory, but
Anakinra had to be stopped due to hypersensitivity
reactions.
Conclusions
Based on our data Anakinra could be an effective first-
line treatment in SOJIA, alone or in association with
steroids, reaching a fast clinical and analytical improve-
ment as well as in the classical second-line use. The pre-
dominance of adverse effects in the group treated only
with Anakinra should be more investigated due to our
small number of patients in this group. Pediatric Rheumatology Unit, Department of Pediatrics. Hospital Sant Joan
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